Carl Mellström

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

Amarjeet Tank, S. Claiborne Johnston, Ritika Jain, Pierre Amarenco et autres

Objective: THALES demonstrated that ticagrelor plus aspirin reduced the risk of stroke or death but increased bleeding versus aspirin during the 30 days following a mild-to-moderate acute non-cardioembolic ischaemic stroke (AIS) or high-risk transient ischaemic attack (TIA). There are no cost-effectiveness analyses …

gb, in, se, us, es, cn (code pays fourni par la source)

Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease

James O. Burton, Alaster M. Allum, Alpesh J. Amin, Cecilia M. Linde et autres

ABSTRACT Background Individuals with chronic kidney disease (CKD) hospitalized with hyperkalemia are at risk of hyperkalemia recurrence and re-hospitalization. We present the rationale and design of CONTINUITY, a study to examine the efficacy of continuing sodium zirconium cyclosilicate (SZC)—an oral, highly selective …

gb, us, se, ca (code pays fourni par la source)

Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

Philippe Gabríel Steg, Deepak L. Bhatt, Stefan Karl James, Oliver T. Darlington et autres

AIMS: To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective. Cost-effectiveness and cost-utility of ticagrelor were evaluated in the overall effect of Ticagrelor on Health Outcomes in …

fr, us, se, gb, ca, es (code pays fourni par la source)

Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study

Glen James, Jennifer Kim, Carl Mellström, Kerrie L. Ford et autres

ABSTRACT Background Hyperkalaemia is an electrolyte abnormality associated with adverse clinical outcomes; however, few studies have investigated the relationship with patterns of hyperkalaemia over time. This study explored the impact of time spent in a hyperkalaemic state and variability of serum potassium …

gb, us, se (code pays fourni par la source)

Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers’ Perspective

Thuy Thi Nguyen, Dung Do, Carl Mellström, Tuan Quang Nguyen et autres

vn, se (code pays fourni par la source)

PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA

Phil C. McEwan, Oliver T. Darlington, Mikael Knutsson, Hans Denison et autres

gb, se, fr, us (code pays fourni par la source)

Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis

Stuart Pocock, David B. Brieger, Ruth Owen, Jiyan Chen et autres

OBJECTIVE: To assess associations of health-related quality of life (HRQoL) with patient profile, resource use, cardiovascular (CV) events and mortality in stable patients post-myocardial infarction (MI). METHODS: The global, prospective, observational TIGRIS Study enrolled 9126 patients 1-3 years post-MI. HRQoL was assessed …

gb, us, au, pl, cn, br, ca, pt, fr, de, jp, se (code pays fourni par la source)

Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population

Eric T Wittbrodt, Narinder P. Bhalla, Karolina Andersson Sundell, Phillip R. Hunt et autres

AIMS: THEMIS (NCT01991795) demonstrated cardioprotective benefits of ticagrelor plus acetylsalicylic acid (ASA) compared with placebo plus ASA in patients with type 2 diabetes (T2D), stable coronary artery disease (CAD) and no history of myocardial infarction (MI) or stroke. To complement these findings, …

fr, us, se, ch (code pays fourni par la source)

Age in relation to comorbidity and outcome in patients with high-risk TIA or minor ischemic stroke: A Swedish national observational study

Oskar Fasth, Eva Lesén, Peter Appelros, Bahman Y. Farahmand et autres

INTRODUCTION: Recent trials report positive results for preventing vascular events with dual antiplatelet therapy (DAPT) in patients with high-risk TIA or minor ischemic stroke. We aimed to investigate this population regarding influence of age on vascular risk factors, hospital stay and mortality. …

se, nl, fi (code pays fourni par la source)

Diabetes association with self‐reported health, resource utilization, and prognosis post‐myocardial infarction

José Carlos Nicolau, David B. Brieger, Ruth Owen, Remo H.M. Furtado et autres

BACKGROUND: Diabetes mellitus (DM) is associated with increased cardiovascular (CV) risk. We compared health-related quality of life (HRQoL), healthcare resource utilization (HRU), and clinical outcomes of stable post-myocardial infarction (MI) patients with and without DM. HYPOTHESIS: In post-MI patients, DM is associated …

br, au, us, gb, ca, fr, de, jp, cn, se (code pays fourni par la source)

Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease with a history of PCI: an economic evaluation of THEMIS-PCI using a Swedish healthcare perpective

Philippe Gabríel Steg, Deepak L. Bhatt, Stephanie James, Oliver T. Darlington et autres

Abstract Background The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) evaluated ticagrelor compared to placebo for the prevention of myocardial infarction (MI), stroke and cardiovascular (CV) death in 19 220 patients with type 2 diabetes (T2DM) …

fr, us, gb, ca, se (code pays fourni par la source)

Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry

Eric T Wittbrodt, Narinder P. Bhalla, Karolina Andersson Sundell, Qi Gao et autres

BACKGROUND: THEMIS (NCT01991795) showed that in patients with type 2 diabetes (T2D) and stable coronary artery disease (CAD) but with no prior myocardial infarction (MI) or stroke, ticagrelor plus acetylsalicylic acid (ASA) decreased the incidence of ischaemic cardiovascular events compared with placebo …

us, se (code pays fourni par la source)